Highlights

• BLS operates pharmaceutical Manufacturing and wholesale activities through its Breathe Life Sciences Business in Australia and international markets.

• The company holds Australian manufacturing and controlled-substance authorisations supporting regulated Supply within the limits of its licences.

• Its Dr Watson Brand covers prescription and consumer health products distributed across several markets and different product formats.

• BLS shares traded at AUD 0.935 on 5 November 2026, with the stock unchanged for the session.

A business built around regulated manufacturing has more moving parts than a single medicine. BLS Pharmaceuticals Limited (ASX:BLS) combines Australian pharmaceutical production, specialist distribution and consumer health brands across multiple international markets. On 5 November 2026, its shares traded at AUD 0.935, unchanged on the day. The company’s operating footprint, authorisations and product range provide the context for that share-price snapshot.

Australian Manufacturing Provides the Operational Base

Through its wholly owned Breathe Life Sciences business, BLS manufactures and distributes medicinal and consumer health products. Its Australian operations hold a Therapeutic Goods Administration manufacturing licence, alongside licences covering the import, export and wholesale supply of specified controlled substances. Those authorisations are important to understanding the business model: pharmaceutical production and regulated distribution depend on the scope of approvals and the requirements applying to individual products. The company describes its Australian activities as primarily business-to-business, serving customers through manufacturing and wholesale relationships rather than relying solely on direct retail. Its range includes medicinal cannabis, investigational medicines and specialist dose forms. These operations distinguish its manufacturing function from the commercial reach of its consumer-facing brands.

Overseas Operations Widen the Distribution Footprint

The group identifies Operating Activities across the United Kingdom, Europe, Japan and the United States, in addition to Australia. Its overseas network includes manufacturing and distribution centres in selected markets, while arrangements and product categories vary by jurisdiction. Rather than presenting every market as identical, the company frames its international business around regulatory pathways, manufacturing capabilities and local routes to customers. BLS is continuing to scale its Australian business and identifies expansion in Germany, the United Kingdom and Europe as a 2026 priority. International distribution is therefore a defined strategic activity, although the availability and commercial position of specific medicines cannot be assumed to be the same in each country.

Brands and Product Development Connect the Business

Dr Watson is the company's branded prescription and consumer health range. Its products span formats such as capsules, tablets, oral solutions and herbal preparations, with formulations incorporating ingredients including probiotics and mushroom extracts. Alongside this branded activity, BLS undertakes contract manufacturing and research into formulations and manufacturing processes. Its stated development work includes patented probiotic capsules and medicines intended for clinical use. Research and production are separate stages: work on a product does not itself establish a regulatory approval, commercial launch or resulting revenue. The combination of contract services and proprietary branding nevertheless explains why the company operates across both pharmaceutical and consumer health channels.

Share Trading and the Priorities Ahead

Shares were quoted at AUD 0.935 on 5 November, within a daily range of AUD 0.930 to AUD 0.970. Reported turnover was 107,373 shares and Market Capitalisation was AUD 220.72 million. The stock's reported one-year change was a gain of 133.75%. These figures describe market trading, not an operational result. BLS identifies manufacturing scale, geographic distribution and development of novel product formats as ongoing priorities. Investors assessing later company releases can distinguish progress in manufacturing capacity and commercial distribution from research-stage activity, while considering the regulatory conditions attached to each product and jurisdiction.